Liver Cancer Protein Hijacks Fat Metabolism to Fuel Tumor Growth and Spread
Scientists discover how PDAP1 protein reprograms liver cells to burn less fat and make more, driving hepatocellular carcinoma progression.
Summary
Researchers identified how a protein called PDAP1 drives liver cancer progression by completely rewiring how cells process fats. In healthy liver cells, there's a balance between making new fats and burning existing ones for energy. PDAP1 disrupts this balance by increasing fat production while decreasing fat burning, creating an environment that fuels tumor growth and spread. The protein works by stabilizing another protein (HSPA8) that activates cellular pathways controlling fat metabolism. Higher PDAP1 levels correlated with worse survival outcomes in liver cancer patients, suggesting it could serve as both a prognostic marker and therapeutic target for this aggressive cancer.
Detailed Summary
This groundbreaking study reveals how liver cancer cells hijack normal fat metabolism to fuel their aggressive growth and spread throughout the body. Understanding this mechanism could lead to new therapeutic approaches for hepatocellular carcinoma, one of the deadliest cancers worldwide.
Researchers investigated PDAP1, a protein that binds to RNA molecules and is overproduced in various cancers. They analyzed patient data, conducted laboratory experiments with cancer cell lines, and tested effects in multiple mouse models including tumor growth and metastasis studies.
The team discovered that PDAP1 fundamentally reprograms how liver cancer cells handle fats. Normally, cells maintain a balance between creating new fatty acids and burning existing ones for energy. PDAP1 disrupts this balance by stabilizing HSPA8 protein, which activates ERK/MAPK signaling pathways. This cascade increases SREBP1 activity (promoting fat synthesis) while suppressing PPARα (reducing fat burning), creating a metabolic environment that supports rapid tumor growth and spread.
Patients with higher PDAP1 levels showed significantly worse survival outcomes, and laboratory studies confirmed that reducing PDAP1 slowed cancer cell growth, migration, and invasion while promoting cancer cell death. Conversely, increasing PDAP1 accelerated these malignant behaviors.
These findings suggest that targeting PDAP1 or its downstream metabolic pathways could offer new treatment strategies for liver cancer. However, this research was conducted primarily in laboratory settings and animal models, so clinical applications remain years away pending human trials and safety studies.
Key Findings
- PDAP1 protein levels predict liver cancer survival outcomes in patients
- PDAP1 increases fat production while decreasing fat burning in cancer cells
- Blocking PDAP1 reduces tumor growth and spread in laboratory studies
- PDAP1 works through HSPA8 protein to activate cancer-promoting pathways
- Metabolic reprogramming drives liver cancer progression and metastasis
Methodology
Researchers used patient databases, laboratory cell culture experiments, and multiple mouse models including subcutaneous tumors, liver tumors, and metastasis studies. They employed RNA sequencing, protein binding assays, and metabolic measurements to understand mechanisms.
Study Limitations
Study conducted primarily in laboratory settings and animal models. Human clinical validation needed. Unclear whether findings apply to other cancer types or if targeting PDAP1 would affect normal liver metabolism.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.